权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Lysosomal-mitochondrial signaling in non-apoptotic cancer cell death

非凋亡癌细胞死亡中的溶酶体线粒体信号传导

基本信息

批准号：
10918534
负责人：
KERMIT L CARRAWAY
金额：
$ 7.91万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10918534
关键词：
Amiloride Apoptosis Apoptotic Autophagocytosis Biochemical Biological Breast Cancer Cell Caspase Cathepsins Cell Cycle Cell Death Cell Death Induction Cell Death Process Cell Differentiation process Cell Membrane Permeability Cell Survival Cell membrane Cell model Cells Ceramides Cessation of life Clinical Communication Complement Cytosol DNA Sequence Alteration Development Disease Disease Management Diuretics Drug Modelings Drug resistance ERBB2 gene Enzymes Event Failure Future Genes Genetic Goals Induction of Apoptosis Lactosylceramides Lead Lipids Lysophosphatidylcholines Lysosomal Storage Diseases Lysosomes Malignant - descriptor Mammalian Cell Mammary Neoplasms Mediating Membrane Membrane Lipids Metabolism Mitochondria Modeling Molecular Molecular Target Morphology Necrosis Normal Cell Organelles Pathway interactions Patient-Focused Outcomes Peptide Hydrolases Permeability Pharmaceutical Preparations Phenotype Potassium Production Publishing Reactive Oxygen Species Recurrent Malignant Neoplasm Recurrent tumor Reporting Resistance Rupture Second Messenger Systems Secondary to Signal Transduction Sphingolipidoses Sphingomyelins Supplementation Testing Therapeutic Therapeutic Agents Tissues Tumor Subtype amphiphilicity bis(monoacylglyceryl)phosphate blood pressure control cancer cell cancer recurrence cancer stem cell cell transformation cell type cytotoxic cytotoxicity improved insight knock-down lipid metabolism lipidomics metabolomics metaplastic cell transformation molecular modeling neoplastic cell novel novel anticancer drug novel strategies novel therapeutics overexpression oxidation peroxidation response stem cell population stem cells targeted treatment therapy resistant tool tumor

项目摘要

PROJECT SUMMARY The overwhelming majority of conventional and targeted chemotherapeutics in clinical use or under development rely on engaging apoptotic pathways to elicit tumor cell death. However, resistance to apoptosis- inducing agents is a particularly thorny clinical problem. A novel approach to targeting therapy-resistant cells is to engage cell death mechanisms other than apoptosis to eradicate these malignant subpopulations. The overall goal of the proposed studies is to define the lysosomal-mitochondrial inter-organelle signaling mechanisms underlying tumor cell-specific and programmed necrotic lysosomal cell death (LCD) process induced by a number of drugs. Our lead compound hexamethylene amiloride (HMA), a derivative of a drug that has been employed clinically in the management of blood pressure for over forty-five years, kills differentiated and stem cancer cells independent of tumor type, subtype, or species, but does not efficiently kill normal differentiated cells or stem cells. Moreover, HMA kills cancer cells independent of cell cycle, autophagy engagement, and caspase-dependent apoptosis; indeed, cell death appears to result from drug-induced permeabilization of the lysosomal limiting membrane and subsequent cathepsin-mediated plasma membrane rupture. Our observations indicate that efficient HMA-induced cell death requires the production and action of mitochondrially-produced reactive oxygen species (ROS). Our observations also indicate that HMA induces hallmarks of some of the sphingolipidosis lysosomal storage diseases, including the accumulation of a variety of lipid species that are normally broken down by the lysosome. Notably, lipids such as lactosylceramide and lysophosphatidylcholine that have been demonstrated to act as signaling second messengers in the production of mitochondrial ROS accumulate specifically in tumor cells but not normal cells upon HMA treatment. Our observations point to a model where drug-induced aberrant lipid accumulation and ROS-mediated lysosomal membrane lipid oxidation disrupt lysosomal membrane integrity, allowing cathepsin release and induction of necrotic cell death. To test this model, we will use biochemical, cell biological and metabolomics approaches. In Aim 1 we will assess the contribution of bis(monoacylglycerol)phosphate (BMP), a lysosome resident lipid that is suppressed in tumor relative normal cells and is further suppressed with HMA treatment, in regulating lysosomal membrane stability and cell viability via its ability to activate lysosomal enzymes of the sphingomyelin breakdown pathway. Complementing these studies will be an in-depth analysis of lipidomic and metabolomic changes associated with cellular transformation and LCD-inducing agents. In Aim 2, we will examine lysosomal-mitochondrial signaling events that couple mitochondrial ROS production to dysregulated lysosomal lipid metabolism. These studies will uncover lysosomal targets that will allow future development of novel therapeutic agents that more effectively elicit cancer cell-specific programmed necrotic cell death.

项目总结绝大多数临床使用或以下的常规和靶向化疗药物发育依赖于参与凋亡途径来诱导肿瘤细胞死亡。然而，对细胞凋亡的抵抗-- 诱导剂是一个特别棘手的临床问题。靶向治疗耐药细胞的一种新方法是利用细胞死亡机制而不是细胞凋亡来根除这些恶性亚群。这个拟议研究的总体目标是定义溶酶体-线粒体细胞器间信号转导肿瘤细胞特异性和程序性坏死溶酶体细胞死亡(LCD)过程的机制由多种药物引起的。我们的先导化合物六亚甲基阿米洛利(HMA)，是一种药物的衍生品已在临床上应用于血压管理超过45年，死亡分化和干细胞，独立于肿瘤类型、亚型或种类，但不能有效地杀死正常分化细胞或干细胞。此外，HMA杀死癌细胞不依赖于细胞周期、自噬参与和caspase依赖的细胞凋亡；事实上，细胞死亡似乎是药物诱导的结果。溶酶体限膜和随后的组织蛋白酶介导的质膜的通透性破裂。我们的观察表明，有效的HMA诱导的细胞死亡需要产生和作用于线粒体产生的活性氧(ROS)。我们的观察还表明，HMA诱导鞘磷脂沉积症溶酶体储存疾病的一些特征，包括各种积聚通常被溶酶体分解的脂类。值得注意的是，诸如乳糖基神经酰胺和溶血磷脂酰胆碱已被证明在生产中充当信号第二信使在HMA处理后，线粒体ROS特异性地聚集在肿瘤细胞中，而不是正常细胞中。我们的观察指向一种模型，其中药物诱导异常脂质堆积和ROS介导的溶酶体膜脂氧化破坏溶酶体膜的完整性，允许组织蛋白酶的释放和诱导坏死性细胞死亡。为了测试这个模型，我们将使用生化、细胞生物学和代谢组学方法。在目标1中，我们将评估双(单甘油)磷酸(BMP)，一种溶酶体驻留的脂质的贡献。在肿瘤相对正常的细胞中被抑制，并被HMA治疗进一步抑制，在调节溶酶体膜的稳定性和细胞活力通过其激活溶酶体酶的能力鞘磷脂的分解途径。对这些研究的补充将是对脂肪组学和与细胞转化和LCD诱导剂相关的代谢变化。在目标2中，我们将研究溶酶体-线粒体信号事件将线粒体ROS的产生与失调联系在一起溶酶体脂代谢。这些研究将揭示溶酶体靶标，使未来能够发展更有效地诱导癌细胞特异性程序性坏死细胞死亡的新型治疗剂。